Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (EPOC)
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Novara, Italia, 28100
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Italia, 60126
- Novartis Investigative Site
-
-
BI
-
Ponderano, BI, Italia, 13900
- Novartis Investigative Site
-
-
CL
-
Caltanissetta, CL, Italia, 93100
- Novartis Investigative Site
-
-
CN
-
Cuneo, CN, Italia, 12100
- Novartis Investigative Site
-
-
CO
-
Como, CO, Italia, 22100
- Novartis Investigative Site
-
-
CT
-
Catania, CT, Italia, 95122
- Novartis Investigative Site
-
-
FG
-
Foggia, FG, Italia, 71100
- Novartis Investigative Site
-
-
FI
-
Castelfiorentino, FI, Italia, 50051
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italia, 20133
- Novartis Investigative Site
-
Milano, MI, Italia, 20122
- Novartis Investigative Site
-
San Donato Milanese, MI, Italia, 20097
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italia, 41100
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Italia, 90146
- Novartis Investigative Site
-
Palermo, PA, Italia, 90129
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italia, 56126
- Novartis Investigative Site
-
-
VR
-
Legnago, VR, Italia, 37045
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients must be diagnosed with relapsing remitting MS (RRMS) as defined by 2005 revised McDonald criteria.
- Patients who explicitly agree to be assigned to a treatment group that may receive fingolimod or DMT after having been informed about their respective benefits and possible adverse events by the investigator.
- An Expanded Disability Status Scale (EDSS) score of 0-5.5 inclusive.
- Must have received continuous treatment with a single approved and indicated MS DMT for a minimum of 6 months prior to the screening visit. Patients must continue with this MS DMT until the randomization visit.
- Naïve to treatment with fingolimod.
Exclusion Criteria:
- A manifestation of MS other than those defined in the inclusion criteria.
- A history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Patients with uncontrolled diabetes mellitus (HbA1c > 7%).
- Diagnosis of macular edema during Screening Phase.
Other protocol-defined inclusion/exclusion criteria may apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Fingolimod
Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
|
Cápsula oral de 0,5 mg/día
Otros nombres:
|
|
Comparador activo: Multiple Sclerosis Disease Modifying Treatment (MS DMT)
Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
|
Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Patient-reported Treatment Satisfaction
Periodo de tiempo: baseline, 6 months
|
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication.
It consists of 3 subscales: effectiveness, convenience and global satisfaction.
The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction.
The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range.
The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction.
This provided a transformed score between 0 and 1 that was then multiplied by 100.
A positive change from baseline indicates improvement.
|
baseline, 6 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in Patient-reported Activities of Daily Living (ADL)
Periodo de tiempo: baseline, 6 months
|
The PRIMUS activity measure is a 15-item assessment used to evaluate patient-reported activities of daily living.
The PRIMUS activities score was calculated summing the 15 items, after recoding the responses from 1 - 3 to 0 - 2. Therefore, the total score ranged from 0 - 3-, where high scores were indicative of greater function limitation.
A negative change from baseline indicates improvement.
|
baseline, 6 months
|
|
Change From Baseline in Patient-reported Fatigue
Periodo de tiempo: 6 months
|
The fatigue Severity Scale (FSS) is a 9-item scale used to assess fatigue.
The FSS score was calculated summing the 9 items of the questionnaire and dividing by the number of non-missing items (each item is based on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)).
A negative change from baseline indicates improvement.
|
6 months
|
|
Change From Baseline in Patient-Reported Effectiveness and Convenience
Periodo de tiempo: 6 months
|
The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication.
It consists of 3 subscales: effectiveness, convenience and global satisfaction.
The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction.
The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range.
The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction.
This provided a transformed score between 0 and 1 that was then multiplied by 100.
A positive change from baseline indicates improvement.
|
6 months
|
|
Change From Baseline in Patient-reported Depression
Periodo de tiempo: 6 months
|
The Beck Depression Inventory Fast Screen (BDI-FS) is a brief, multiple choice, self reported inventory designed to evaluate depression in patients with medical illness.
The BDI-FS score was calculated summing the 7 items of the questionnaire.
Each item ranged from 0 (not present) to 3 (severe).
The total score ranges from 0-3 (minimal depression), 4-8 (mild depression), 9-12 (moderate depression) and 13-21 (severe depression).
A negative change from baseline indicates improvement.
|
6 months
|
|
Change From Baseline in Patient-reported Health Related Quality of Life (QOL)
Periodo de tiempo: 6 months
|
The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS.
It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, pain, general health, energy/fatigue, social functioning, role limitations due to emotional problems and emotional well-being.
Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
If half or more questions within a domain were answered, then a score was calculated for that domain.
Otherwise, the patient score for that domain was set to missing.
If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing.
An algorithm was used to create a score from 0 to 100 for each domain score and component score.
A positive change from baseline indicates improvement.
|
6 months
|
|
Physician-reported Clinical Global Impression of Improvement (CGI-I)
Periodo de tiempo: 6 months
|
The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time.
The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse.
A lower score and a negative change from baseline indicate improvement.
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Renato Turrini, MD, Novartis Farma S.p.A.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades del Sistema Nervioso
- Enfermedades del sistema inmunológico
- Enfermedades Autoinmunes Desmielinizantes, SNC
- Enfermedades Autoinmunes del Sistema Nervioso
- Enfermedades desmielinizantes
- Enfermedades autoinmunes
- Esclerosis múltiple
- Esclerosis
- Esclerosis Múltiple Recurrente-Remitente
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes inmunosupresores
- Factores inmunológicos
- Adyuvantes, Inmunológicos
- Moduladores del receptor de fosfato de esfingosina 1
- Clorhidrato de fingolimod
- Interferón beta-1b
Otros números de identificación del estudio
Otros números de identificación del estudio
- CFTY720DIT02
- 2010-024017-31 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .